We furthermore show that preventing RBPJ/NICD complex formation re-sensitized CRT-refractory tumor cells and thus offers a promising therapeutic strategy to solve the problems that come along with CRT resistance in rectal cancer. This evidence concerns the gene RBPJ and rectal cancer.